Join
Live feed
·
PRReleasevia Quantisnow
Syndax Pharmaceuticals Inc. logo

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

ByQuantisnow·Wall Street's wire, on your screen.
SNDX· Syndax Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNDX (Syndax Pharmaceuticals Inc.) and more on Quantisnow.